Amarin Corporation plc

Amarin Corporation plc is an Irish-American biopharmaceutical company dedicated to improving cardiovascular health and reducing the burden of cardiovascular disease, which remains a leading cause of death globally. Founded in 1993, the company operates with dual headquarters in Dublin, Ireland, and Bridgewater, New Jersey, USA. Its mission centers on developing and commercializing innovative therapeutics to address unmet medical needs in cardiovascular care.

The company's primary product is VASCEPA® (icosapent ethyl), a prescription-grade omega-3 fatty acid. Initially approved by the U.S. Food and Drug Administration (FDA) in 2012 for severe hypertriglyceridemia, its indication was expanded in 2019 to reduce cardiovascular risk in adult patients with elevated triglycerides and other risk factors. Marketed as VAZKEPA in Europe, this product forms the core of Amarin's efforts to provide evidence-based therapies for cardiovascular risk reduction.

Under the leadership of President and CEO Aaron Berg, appointed in June 2024, Amarin is navigating a dynamic market landscape. The company reported a 7.4% year-over-year increase in total net revenue for Q1 2026, reaching $45.1 million, alongside a 31% reduction in operating expenses due to restructuring efforts. Amarin narrowed its operating loss and generated positive cash flow for the second consecutive quarter, ending Q1 2026 with $307.8 million in cash and investments. Facing generic competition in the U.S., Amarin has strategically pivoted towards global expansion, notably through a partnership with Recordati for the European commercialization of VAZKEPA, which has launched in 10 countries. The company anticipates being cash-flow positive for the full year 2026.